| Identification | Back Directory | [Name]
2-Piperidineethanol, 1-[3-ethyl-7-[(3-pyridinylMethyl)aMino]pyrazolo[1,5-a]pyriMidin-5-yl]-, (2S)- | [CAS]
779353-02-5 | [Synonyms]
CDK-IN-6
2-Piperidineethanol, 1-[3-ethyl-7-[(3-pyridinylMethyl)aMino]pyrazolo[1,5-a]pyriMidin-5-yl]-, (2S)-
(S)-2-(1-(3-ethyl-7-((pyridin-3-ylmethyl)amino)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-2-yl)ethanol | [Molecular Formula]
C21H28N6O | [MDL Number]
MFCD28167881 | [MOL File]
779353-02-5.mol | [Molecular Weight]
380.487 |
| Chemical Properties | Back Directory | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (131.41 mM; Need ultrasonic) | [form ]
Solid | [pka]
15.15±0.10(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Biological Activity]
CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a CDK inhibitor with anticancer activities[1].
Individual CDK’s, such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8 and the like, perform distinct roles in cell cycle progression and can be classified as either G1, S, or G2M phase enzymes. Uncontrolled proliferation is a hallmark of cancer cells, and misregulation of CDK function occurs with high frequency in many important solid tumors[1]. | [storage]
Store at -20°C | [References]
[1]. Timothy Guzi, et al. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. US20040209878A1. |
|
|